Lastiri José M, Specterman Sergio R, Rendo Pablo, Pallotta María G, Varela Mirta S, Goldstein Sofía
Sección Oncología, Hospital Italiano de Buenos Aires, Gascón 450, 1181 Buenos Aires, Argentina.
Medicina (B Aires). 2002;62(1):41-7.
The use of human recombinant erythropoietin (rHuEpo) has been approved by the Food and Drug Administration (FDA) in patients with anemia and cancer. Although good results have been obtained, it is too expensive to permit its use massively. For the purpose of evaluating the therapeutic effect of rHuEpo, including toxicity, predictive response variables and quality of life parameters, a prospective trial was carried out in patients with anemia and cancer. Hematimetric parameters, ferritin, Epo, cytokines, transfusions and quality of life were registered. A total of 36 patients were treated in the protocol (34 were evaluable): 16 men and 20 women, with a medium age 56.4 years; 27 patients were treated with chemotherapy (16 with cisplatinum); 15 patients presented medullar infiltration. In 73.5% patients an increase in the level of hemoglobin was registered, and in 64.7% its normalisation was attained. Transfusional requirements were reduced by 50%. The hemoglobin increase greater than 0.5 g/dl at the second week of treatment was the most significant variable of early response. Patients treated with cisplatinum, seric ferritin lower than 1,100 ng/dl and those without medullar tumoral infiltration responded best. Serum Epo, cytokines (IL-1, IL-6 and TNF) and reticulocyte count at the second week did not correlate with response. Quality of life parameters were better in patients with good response to rHuEpo. It can be concluded that good results in the treatment of patients with anemia and cancer are obtained with rHuEpo.
人重组促红细胞生成素（rHuEpo）已获美国食品药品监督管理局（FDA）批准用于贫血和癌症患者。尽管已取得良好效果，但因其价格昂贵，无法大规模使用。为评估rHuEpo的治疗效果，包括毒性、预测反应变量和生活质量参数，对贫血和癌症患者进行了一项前瞻性试验。记录了血液学参数、铁蛋白、促红细胞生成素、细胞因子、输血情况和生活质量。共有36例患者按方案接受治疗（34例可评估）：16例男性和20例女性，平均年龄56.4岁；27例患者接受化疗（16例使用顺铂）；15例患者出现骨髓浸润。73.5%的患者血红蛋白水平升高，64.7%的患者血红蛋白恢复正常。输血需求减少了50%。治疗第二周血红蛋白升高大于0.5 g/dl是早期反应最显著的变量。接受顺铂治疗、血清铁蛋白低于1100 ng/dl且无骨髓肿瘤浸润的患者反应最佳。治疗第二周的血清促红细胞生成素、细胞因子（IL-1、IL-6和TNF）和网织红细胞计数与反应无关。rHuEpo反应良好的患者生活质量参数更佳。可以得出结论，rHuEpo治疗贫血和癌症患者取得了良好效果。
